New insights into diabetic polyneuropathy

被引:80
作者
Polydefkis, M
Griffin, JW
McArthur, J
机构
[1] Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA
[3] Johns Hopkins Univ Hosp, Dept Neurosci, Baltimore, MD 21287 USA
[4] Johns Hopkins Univ Hosp, Dept Epidemiol, Baltimore, MD 21287 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2003年 / 290卷 / 10期
关键词
D O I
10.1001/jama.290.10.1371
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with complaints of numbness, tingling, and dysesthesias in the toes and feet are frequently referred to neurologists. Often, the only objective evidence for peripheral nerve dysfunction in these patients is limited to small-caliber sensory nerve fibers. On examination these patients may have reduced distal pinprick sensation, and distal leg skin biopsies show loss of small-caliber nerve fibers. Studies focusing on small-caliber nerve fibers have led to a growing impression that neuropathy can be associated with early diabetes or impaired glucose tolerance (IGT). Often, neuropathy can be the presenting symptom of either diabetes or IGT. Furthermore, the oral glucose tolerance test appears to be a more sensitive measure of glucose dys-metabolism in these patients than levels of fasting blood glucose or glycated hemoglobin. Patients with IGT-associated neuropathy may represent an attractive target population for future regenerative studies given that their neuropathy is less severe and presumably more easily reversed than neuropathy occurring in patients with diabetes. Historically, small-caliber fibers have not been extensively evaluated due to a lack of objective measures. Several measures to evaluate these fibers are emerging, including skin biopsy with visualization of epidermal nerve fibers. The accessibility of epidermal nerve fibers makes them an attractive target for nerve injury models, which have potential for development as novel outcome measures. Such approaches may address some of the challenges of past diabetic polyneuropathy trials.
引用
收藏
页码:1371 / 1376
页数:6
相关论文
共 61 条
[51]   Impaired glucose tolerance - Does it cause neuropathy? [J].
Russell, JW ;
Feldman, EL .
MUSCLE & NERVE, 2001, 24 (09) :1109-1112
[52]  
Simone DA, 1998, J NEUROSCI, V18, P8947
[53]  
Simoneau Guy G, DIABETES CARE, V17, P1411, DOI [10.2337/diacare.17.12.1411, DOI 10.2337/DIACARE.17.12.1411, DOI 10.2337/DIACARE.25.2007.S33]
[54]   Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy [J].
Singleton, JR ;
Smith, AG ;
Bromberg, MB .
DIABETES CARE, 2001, 24 (08) :1448-1453
[55]   Painful sensory polyneuropathy associated with impaired glucose tolerance [J].
Singleton, JR ;
Smith, AG ;
Bromberg, MB .
MUSCLE & NERVE, 2001, 24 (09) :1225-1228
[56]   Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy [J].
Smith, AG ;
Ramachandran, P ;
Tripp, S ;
Singleton, JR .
NEUROLOGY, 2001, 57 (09) :1701-1704
[57]   The spectrum of neuropathy in diabetes and impaired glucose tolerance [J].
Sumner, CJ ;
Sheth, S ;
Griffin, JW ;
Cornblath, DR ;
Polydefkis, M .
NEUROLOGY, 2003, 60 (01) :108-111
[58]   PGP 9.5 - A NEW MARKER FOR VERTEBRATE NEURONS AND NEUROENDOCRINE CELLS [J].
THOMPSON, RJ ;
DORAN, JF ;
JACKSON, P ;
DHILLON, AP ;
RODE, J .
BRAIN RESEARCH, 1983, 278 (1-2) :224-228
[59]   Point: A glucose tolerance test is important for clinical pratice [J].
Tuomilehto, J .
DIABETES CARE, 2002, 25 (10) :1880-1882
[60]   PROTEIN GENE-PRODUCT 9.5-IMMUNOREACTIVE NERVE-FIBERS AND CELLS IN HUMAN SKIN [J].
WANG, LX ;
HILLIGES, M ;
JERNBERG, T ;
WIEGLEBEDSTROM, D ;
JOHANSSON, O .
CELL AND TISSUE RESEARCH, 1990, 261 (01) :25-33